Vaxcyte shares jump after late-stage vaccine trial results
Vaxcyte stock surged after late-stage results suggested its lead vaccine candidate could steal significant share from Pfizer and Merck in a multi-billion-dollar market.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.